Annual CFF
$472.43 M
+$401.54 M+566.47%
31 March 2024
Summary:
Immunovant annual cash flow from financing activities is currently $472.43 million, with the most recent change of +$401.54 million (+566.47%) on 31 March 2024. During the last 3 years, it has risen by +$89.31 million (+23.31%). IMVT annual CFF is now at all-time high.IMVT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$730.00 K
+$44.00 K+6.41%
30 September 2024
Summary:
Immunovant quarterly cash flow from financing activities is currently $730.00 thousand, with the most recent change of +$44.00 thousand (+6.41%) on 30 September 2024. Over the past year, it has increased by +$582.00 thousand (+393.24%). IMVT quarterly CFF is now -99.84% below its all-time high of $469.84 million, reached on 31 December 2023.IMVT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$472.81 M
+$582.00 K+0.12%
30 September 2024
Summary:
Immunovant TTM cash flow from financing activities is currently $472.81 million, with the most recent change of +$582.00 thousand (+0.12%) on 30 September 2024. Over the past year, it has increased by +$400.90 million (+557.57%). IMVT TTM CFF is now at all-time high.IMVT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMVT Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +566.5% | +393.2% | +557.6% |
| 3 y3 years | +23.3% | -99.6% | +134.8% |
| 5 y5 years | - | +100.0% | +304.7% |
IMVT Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +566.5% | -99.8% | at high | >+9999.0% | |
| 5 y | 5 years | at high | +566.5% | -99.8% | at high | >+9999.0% | |
| alltime | all time | at high | +566.5% | -99.8% | +513.1% | at high | >+9999.0% |
Immunovant Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $730.00 K(+6.4%) | $472.81 M(+0.1%) |
| June 2024 | - | $686.00 K(-55.6%) | $472.22 M(-0.0%) |
| Mar 2024 | $472.43 M(+566.5%) | $1.54 M(-99.7%) | $472.43 M(+0.3%) |
| Dec 2023 | - | $469.84 M(>+9900.0%) | $471.12 M(+555.2%) |
| Sept 2023 | - | $148.00 K(-83.4%) | $71.90 M(+0.2%) |
| June 2023 | - | $890.00 K(+282.0%) | $71.75 M(+1.2%) |
| Mar 2023 | $70.89 M(-64.6%) | $233.00 K(-99.7%) | $70.89 M(+0.3%) |
| Dec 2022 | - | $70.63 M(>+9900.0%) | $70.65 M(>+9900.0%) |
| Sept 2022 | - | $0.00(-100.0%) | $21.00 K(-100.0%) |
| June 2022 | - | $21.00 K(>+9900.0%) | $200.06 M(-0.0%) |
| Mar 2022 | $200.13 M | $0.00(0.0%) | $200.13 M(-0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | - | $0.00(-100.0%) | $200.89 M(-0.2%) |
| Sept 2021 | - | $200.04 M(>+9900.0%) | $201.34 M(+6.2%) |
| June 2021 | - | $91.00 K(-88.1%) | $189.65 M(-50.5%) |
| Mar 2021 | $383.11 M(+160.7%) | $763.00 K(+71.1%) | $383.11 M(+0.2%) |
| Dec 2020 | - | $446.00 K(-99.8%) | $382.35 M(+0.1%) |
| Sept 2020 | - | $188.35 M(-2.7%) | $381.90 M(+97.3%) |
| June 2020 | - | $193.55 M(>+9900.0%) | $193.55 M(+65.7%) |
| Mar 2020 | $146.97 M | - | - |
| Sept 2019 | - | $0.00(-100.0%) | $116.82 M(0.0%) |
| June 2019 | - | $116.99 M(<-9900.0%) | $116.82 M(<-9900.0%) |
| Mar 2019 | - | -$176.70 K | -$176.70 K |
FAQ
- What is Immunovant annual cash flow from financing activities?
- What is the all time high annual CFF for Immunovant?
- What is Immunovant annual CFF year-on-year change?
- What is Immunovant quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Immunovant?
- What is Immunovant quarterly CFF year-on-year change?
- What is Immunovant TTM cash flow from financing activities?
- What is the all time high TTM CFF for Immunovant?
- What is Immunovant TTM CFF year-on-year change?
What is Immunovant annual cash flow from financing activities?
The current annual CFF of IMVT is $472.43 M
What is the all time high annual CFF for Immunovant?
Immunovant all-time high annual cash flow from financing activities is $472.43 M
What is Immunovant annual CFF year-on-year change?
Over the past year, IMVT annual cash flow from financing activities has changed by +$401.54 M (+566.47%)
What is Immunovant quarterly cash flow from financing activities?
The current quarterly CFF of IMVT is $730.00 K
What is the all time high quarterly CFF for Immunovant?
Immunovant all-time high quarterly cash flow from financing activities is $469.84 M
What is Immunovant quarterly CFF year-on-year change?
Over the past year, IMVT quarterly cash flow from financing activities has changed by +$582.00 K (+393.24%)
What is Immunovant TTM cash flow from financing activities?
The current TTM CFF of IMVT is $472.81 M
What is the all time high TTM CFF for Immunovant?
Immunovant all-time high TTM cash flow from financing activities is $472.81 M
What is Immunovant TTM CFF year-on-year change?
Over the past year, IMVT TTM cash flow from financing activities has changed by +$400.90 M (+557.57%)